• New patents protect engineered probiotic delivery platform and Lactobacillus strains
• Supports BE-101, a novel poultry biologic targeting Clostridium perfringens
• Platform enables in situ delivery of therapeutic biomolecules in the gut
• Expands potential applications across livestock, pets, and human health
• BE-101 advancing toward potential USDA conditional licensure in 2026
BiomEdit has announced the issuance of foundational patents covering its engineered probiotic delivery platform, establishing broad intellectual property protection for its core technology and pipeline of microbiome-based biologics.
The patents, including those covering genetically modified Lactobacillus reuteri strains and their applications, protect both the composition of engineered microbes and the methods used to deliver biologically active molecules directly within a host. The platform is designed to enable localized, sustained expression of therapeutic payloads in the gastrointestinal tract.
Platform Enables Precision Biologic Delivery
The patented technology includes engineered probiotic strains capable of producing therapeutic biomolecules in situ, delivery systems for targeted and sustained expression, and the ability to generate biologically active proteins such as antibodies. One key application includes targeting Clostridium perfringens, a major pathogen responsible for necrotic enteritis in poultry.
The platform is designed to support applications across multiple species, including livestock and companion animals, with potential expansion into human health. BiomEdit said the patents establish a foundation for a new class of precision biologics delivered through well-characterized microbial strains.
Lead Program Targets Poultry Disease Without Antibiotics
The intellectual property directly supports BiomEdit’s lead product, BE-101, a probiotic vectored antibody (pvAb™) biologic designed to neutralize toxins produced by Clostridium perfringens. The approach represents a non-antibiotic strategy for preventing disease and improving production outcomes in broiler chickens.
BE-101 is currently undergoing field studies and regulatory review, with the company targeting potential conditional licensure from the USDA Center for Veterinary Biologics in the third quarter of 2026 and commercial readiness by the fourth quarter.
Pipeline Expansion and Future Applications
Beyond BE-101, the platform is expected to support a range of applications including disease prevention, performance enhancement, and therapeutic interventions across animal health. By combining strain engineering, payload design, and scalable oral delivery, BiomEdit aims to advance microbiome-enabled biologics as alternatives to traditional treatments.
Information sourced from the company’s press release.
